PMID- 16000281
OWN - NLM
STAT- MEDLINE
DCOM- 20050823
LR  - 20181113
IS  - 0161-5505 (Print)
IS  - 0161-5505 (Linking)
VI  - 46
IP  - 7
DP  - 2005 Jul
TI  - 5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume 
      correction.
PG  - 1128-35
AB  - Preclinical studies suggest that serotonin 1A receptors (5-HT 1A) play a role in 
      temporal lobe epilepsy (TLE). Previous PET studies reported decreased 5-HT 1A 
      binding ipsilateral to epileptic foci but did not correct for the partial-volume 
      effect (PVE) due to structural atrophy. METHODS: We used PET with 
      18F-trans-4-fluoro-N-2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl-N-(2-pyridyl)cyclohexanecarboxamide 
      (18F-FCWAY), a 5-HT 1A receptor antagonist, to study 22 patients with TLE and 10 
      control subjects. In patients, 18F-FDG scans also were performed. An automated 
      MR-based partial-volume correction (PVC) algorithm was applied. Psychiatric 
      symptoms were assessed with the Beck Depression Inventory Scale. RESULTS: Before 
      PVC, significant (uncorrected P < 0.05) reductions of 18F-FCWAY binding potential 
      (BP) were detected in both mesial and lateral temporal structures, mainly 
      ipsilateral to the seizure focus, in the insula, and in the raphe. Group 
      differences were maximal in ipsilateral mesial temporal regions (corrected P < 
      0.05). After PVC, differences in mesial, but not lateral, temporal structures and 
      in the insula remained highly significant (corrected P < 0.05). Significant 
      (uncorrected P < 0.05) BP reductions were also detected in TLE patients with 
      normal MR images (n = 6), in mesial temporal structures. After PVC, asymmetries 
      in BP remained significantly greater than for glucose metabolism in hippocampus 
      and parahippocampus. There was a significant inverse relation between the Beck 
      Depression score and the ipsilateral hippocampal BP, both before and after PVC. 
      CONCLUSION: Our study shows that in TLE patients, reductions of 5-HT 1A receptor 
      binding in mesial temporal structures and insula are still significant after PVC. 
      In contrast, partial-volume effects may be an important contributor to 5-HT 1A 
      receptor-binding reductions in lateral temporal lobe. Reduction of 5-HT 1A 
      receptors in the ipsilateral hippocampus may contribute to depressive symptoms in 
      TLE patients.
FAU - Giovacchini, Giampiero
AU  - Giovacchini G
AD  - PET Department, Clinical Center, National Institutes of Health, Bethesda, 
      Maryland 20892-1408, USA.
FAU - Toczek, Maria T
AU  - Toczek MT
FAU - Bonwetsch, Robert
AU  - Bonwetsch R
FAU - Bagic, Anto
AU  - Bagic A
FAU - Lang, Lixin
AU  - Lang L
FAU - Fraser, Charles
AU  - Fraser C
FAU - Reeves-Tyer, Pat
AU  - Reeves-Tyer P
FAU - Herscovitch, Peter
AU  - Herscovitch P
FAU - Eckelman, William C
AU  - Eckelman WC
FAU - Carson, Richard E
AU  - Carson RE
FAU - Theodore, William H
AU  - Theodore WH
LA  - eng
GR  - Z01 NS002236-30/NS/NINDS NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Nucl Med
JT  - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
JID - 0217410
RN  - 0 (Cyclohexanes)
RN  - 0 (Fluorine Radioisotopes)
RN  - 0 (N-(2-(4-(2-methoxyphenyl)piperazino))-N-(2-pyridinyl) 
      trans-4-fluorocyclohexanecarboxamide)
RN  - 0 (Piperazines)
RN  - 0 (Radiopharmaceuticals)
RN  - 112692-38-3 (Receptor, Serotonin, 5-HT1A)
SB  - IM
MH  - Adult
MH  - Algorithms
MH  - Cyclohexanes/*pharmacokinetics
MH  - Epilepsy, Temporal Lobe/*diagnosis/*metabolism
MH  - Female
MH  - Fluorine Radioisotopes/pharmacokinetics
MH  - Humans
MH  - Image Interpretation, Computer-Assisted/*methods
MH  - Imaging, Three-Dimensional/methods
MH  - Magnetic Resonance Imaging/methods
MH  - Male
MH  - Piperazines/*pharmacokinetics
MH  - Radionuclide Imaging
MH  - Radiopharmaceuticals
MH  - Receptor, Serotonin, 5-HT1A/*metabolism
MH  - Severity of Illness Index
MH  - Temporal Lobe/*diagnostic imaging/*metabolism
PMC - PMC1454475
MID - NIHMS6225
EDAT- 2005/07/08 09:00
MHDA- 2005/08/24 09:00
PMCR- 2008/01/26
CRDT- 2005/07/08 09:00
PHST- 2005/07/08 09:00 [pubmed]
PHST- 2005/08/24 09:00 [medline]
PHST- 2005/07/08 09:00 [entrez]
PHST- 2008/01/26 00:00 [pmc-release]
AID - 46/7/1128 [pii]
PST - ppublish
SO  - J Nucl Med. 2005 Jul;46(7):1128-35.